Casdin Capital, LLC Syndax Pharmaceuticals Inc Transaction History
Casdin Capital, LLC
- $1.16 Billion
- Q2 2024
A detailed history of Casdin Capital, LLC transactions in Syndax Pharmaceuticals Inc stock. As of the latest transaction made, Casdin Capital, LLC holds 150,000 shares of SNDX stock, worth $2.96 Million. This represents 0.27% of its overall portfolio holdings.
Number of Shares
150,000
Previous 150,000
-0.0%
Holding current value
$2.96 Million
Previous $3.08 Million
-0.0%
% of portfolio
0.27%
Previous 0.27%
Shares
5 transactions
Others Institutions Holding SNDX
# of Institutions
200Shares Held
87MCall Options Held
268KPut Options Held
76.8K-
Black Rock Inc. New York, NY7.91MShares$156 Million0.0% of portfolio
-
Wellington Management Group LLP Boston, MA7.34MShares$145 Million0.03% of portfolio
-
Kynam Capital Management, LP Princeton, NJ5.72MShares$113 Million9.15% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.8MShares$94.6 Million0.0% of portfolio
-
Avoro Capital Advisors LLC New York, NY3.89MShares$76.6 Million1.09% of portfolio
About Syndax Pharmaceuticals Inc
- Ticker SNDX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 56,565,200
- Market Cap $1.11B
- Description
- Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are SNDX-5613, which is in phase 1/2 clinical trial targeting the binding interaction of Menin with the mixed lineage leukemia 1 protein for the treatment of MLL-rearranged (MLLr) and nucleophosmin...